Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 163-174

  Lo, Roger S ^a   Shi, Hubing ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRAF; Drug resistance; MAPK; MEK; Molecular diagnosis; NRAS; RTK

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; DIAGNOSTIC PROCEDURE; ENZYME INDUCTION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; MELANOMA; MUTANT; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; UP-REGULATION;

EID: 84891819709     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_10     Document Type: Article

References (26)

1. Davies H, Bignell GR et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
2. Bollag G, Hirth P et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599
3. Flaherty KT, Puzanov I et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
4. Chapman PB, Hauschild A et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
5. Hauschild A, Grob J-J et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
6. Falchook GS, Long GV et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901
7. Nazarian R, Shi H et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977
8. Johannessen CM, Boehm JS et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972
9. Poulikakos PI, Persaud Y et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-390
10. Shi H, Moriceau G et al (2012) Melanoma whole-exome sequencing identifi es V600EB-RAF amplifi cation-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724
11. Wagle N, Emery C et al (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096
12. Villanueva J, Vultur A et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695
13. Prahallad A, Sun C et al (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103
14. Corcoran RB, Ebi H et al (2012) EGFRmediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235
15. Yadav V, Zhang X et al (2012) Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287:28087-28098
16. Duncan JS, Whittle MC et al (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149:307-321
17. Shi H, Kong X et al (2011) Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71:5067-5074
18. Vigil D, Cherfi ls J et al (2010) Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy? Nat Rev Cancer 10: 842-857
19. Fedorenko IV, Gibney GT et al (2013) NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management. Oncogene 32(25):3009-3018
20. Flaherty KT, Infante JR et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703
21. Kobayashi S, Boggon TJ et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefi tinib. N Engl J Med 352: 786-792
22. Patel SP, Kim KB (2012) Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 21:531-539
23. Emery CM, Vijayendran KG et al (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci 106:20411-20416
24. Shi H, Moriceau G et al (2012) Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2:414-424
25. Dörrie J, Wellner V et al (2006) An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: Implications for tumor antigen detection and amplifi cation. J Immunol Method 313: 119-128
26. Lagonigro MS, De Cecco L et al (2004) CTAB-urea method purifi es RNA from melanin for cDNA microarray analysis. Pigment Cell Res 17:312-315